Ventyx Biosciences (NASDAQ:VTYX) Earns "Neutral" Rating from HC Wainwright

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report)'s stock had its "neutral" rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $6.00 price objective on the stock. HC Wainwright's price objective indicates a potential upside of 176.50% from the stock's previous close.

VTYX has been the subject of a number of other research reports. Wells Fargo & Company dropped their target price on Ventyx Biosciences from $16.00 to $11.00 and set an "overweight" rating for the company in a report on Monday, August 12th. Oppenheimer restated an "outperform" rating and set a $9.00 target price (down from $10.00) on shares of Ventyx Biosciences in a research report on Friday. Finally, Canaccord Genuity Group cut their price objective on shares of Ventyx Biosciences from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Monday, August 12th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Ventyx Biosciences currently has an average rating of "Moderate Buy" and an average price target of $10.00.

Ventyx Biosciences Price Performance

VTYX stock traded down $0.03 on Monday, hitting $2.17. 488,036 shares of the company were exchanged, compared to its average volume of 2,048,685. Ventyx Biosciences has a twelve month low of $1.79 and a twelve month high of $11.48. The stock has a market capitalization of $153.35 million, a price-to-earnings ratio of -0.92 and a beta of 0.37. The business's fifty day moving average is $2.24 and its two-hundred day moving average is $2.82.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.02). Equities research analysts expect that Ventyx Biosciences will post -2.14 earnings per share for the current year.

Institutional Trading of Ventyx Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. Deerfield Management Company L.P. Series C boosted its position in shares of Ventyx Biosciences by 64.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company's stock valued at $13,466,000 after buying an additional 2,287,570 shares during the period. Farallon Capital Management LLC acquired a new position in shares of Ventyx Biosciences in the 1st quarter valued at about $17,435,000. Redmile Group LLC boosted its position in Ventyx Biosciences by 944.4% during the first quarter. Redmile Group LLC now owns 2,164,126 shares of the company's stock worth $11,903,000 after purchasing an additional 1,956,923 shares in the last quarter. Opaleye Management Inc. raised its holdings in shares of Ventyx Biosciences by 12.7% during the first quarter. Opaleye Management Inc. now owns 1,285,000 shares of the company's stock valued at $7,068,000 after acquiring an additional 145,000 shares during the last quarter. Finally, First Light Asset Management LLC purchased a new position in Ventyx Biosciences in the 1st quarter worth approximately $3,437,000. Institutional investors own 97.88% of the company's stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.